Peck GM, Staat MA, Huang FS, et al. - As of 2017, nine months of isoniazid has been replaced by short course combination regimen of weekly isoniazid and rifapentine (3HP) given by directly observed therapy (DOT) as the standard of treatment for latent tuberculosis in pediatric patients, and superior safety and adherence of the 3HP regimen has been established by literature limited in size, thus, researchers explored this topic by conducting a retrospective chart review (n = 22) including pediatric patients receiving the 3HP regimen via DOT between 2017 and 2019 at their institution. Frequent adverse events, more severe adverse events such as anaphylaxis, and higher treatment cessation were evident in pediatric patients ages 2 to 20 years receiving 3HP with DOT for latent tuberculosis, compared with that which has been previously documented in the literature. The race/ethnicity of this cohort varied from the cohorts detailed in the literature. Overall, these findings indicate the possibility of a higher adverse event rate, than previously established, related to short course combination regimen for pediatric latent tuberculosis patients.